Latest Headlines

Latest Headlines

Analysts: Mylan won't land Perrigo, even with Teva out of the way

Teva's $40.5 billion deal to buy Allergan's generics business ended its pursuit of Mylan and left its rival the chance to snap up its own hostile target, Perrigo. But the way some analysts see it, things won't necessarily go that way.

With new cash on its way, it's back to buying for deal-happy Allergan, CEO says

On Monday, Allergan agreed to sell off a $40.5 billion piece of its business, inking a pact to exit the generics space with a sale to Teva Pharmaceutical Industries. But CEO Brent Saunders is already thinking about future buys.

Mallinckrodt to sell contrast business to French imaging player Guerbet for $270M

German specialty pharma Mallinckrodt has opted to sell off its contrast media and delivery systems business to Paris-based Guerbet for about $270 million as part of a strategic review of its business. The business has had declining revenues, but generates substantial cash and will mean a big step up for Guerbet.

Hard-hit Biogen needs to act fast, analysts say--or beware its deal-hungry peers

Last week was a less-than-ideal one for Biogen--and the Massachusetts company may risk becoming deal bait if it doesn't do something about it quickly.

Hikma shells out $2.65B for Boehringer's U.S. generics business

When Boehringer Ingelheim put its U.S.-based generics business on the market, Hikma Pharmaceuticals, Mallinckrodt and Perrigo reportedly pulled up seats at the bidding table. But Hikma emerged the winner, snagging Boehringer's Roxane Labs unit for $2.65 billion to substantially boost its noninjectable generics business.

Merck signs a $605M deal to bulk up in cancer immunotherapy

Merck, maker of the pioneering immuno-oncology treatment Keytruda, is investing in the next generation of cancer therapies that harness the body's natural defenses, agreeing to pay as much as $605 million for an Israeli biotech at work in the field.

About that brand/generics hybrid thing? Make that brands only, Allergan says with Teva deal

It's been less than 8 months since the company formerly known as Actavis agreed to swallow Allergan, taking a $66 billion plunge into branded sales and pledging to run its branded and generics businesses as "one culture, one company." But it took just a few weeks to undo those plans, as lucky bidder Teva found out with Monday's $40.5 billion deal for the drugmaker's generic offerings.

Allergan joins the hunt for a 'transformational' biotech deal

In a conversation with Forbes ' Matthew Herper, Allergan CEO Brent Saunders happily spotlighted his bolt-on buyouts with Kythera, Naurex, Furiex and Rhythm. Compare that to recent remarks from Eli Lilly's John Lechleiter, who has always insisted on backing the pipeline he has while adding an occasional pact, or Severin Schwan at Roche. Both see this current market as overpriced.

AstraZeneca snags $300M from Sanofi for rare cancer med amid cash-generating deal spree

AstraZeneca CEO Pascal Soriot has long argued that shedding some of the company's noncore businesses could help jump-start sales, adding cash to its reservoirs as it chases its lofty sales goals. Now, the British drugmaker is taking another step in that direction as it passes off one of its rare cancer drugs to Sanofi, getting $300 million in the process.

Forget Mylan: Teva inks $40B-plus pact for Allergan's generics biz

Forget everything you thought you knew last week about some of the generics industry's biggest players. Teva is no longer enmeshed in a hostile pursuit of rival Mylan, and Allergan is no longer touting its status as a hybrid brand-and-generics specialist. Instead, they're teaming up with one another.